Objects : The aim of this study was to determine the pharmacokinetic interaction between fluoxetine and haloperidol after fluoxetine trial in haloperidol-stabilized schizophrenics. Methods : Fluoxetine was added for 6 weeks to stable doses of haloperidol given to 32 schizophrenic inpatients. Then, using a HPLC equipped with UV detector, the authors measured plasma concentrations of haloperidol, reduced haloperidol and total haloperidol. Results : 1) After fluoxetine was added, mean plasma haloperidol concentrations were increased significantly at 2nd week(p<0.05) and were decreased significantly at 6th week(p<0.05). 2) Mean plasma reduced haloperidol concentrations were increased significantly at 2nd week (p<C0.05) and also tended to increase at 6th week, although there was no significant difference of the values between 2nd week and 6th week(p=0.142). 3) Mean plasma total haloperidol concentrations were increased significantly at 2nd week(p<C 0.05), but shown no significant changes between 2nd and 6th week(p=0.848). 4) The ratios between reduced haloperidol concentrations and haloperidol concentrations, reduction ratios were increased significantly at 6th week(p<C0.05). Conclusionss : We suggest that the elevation of plasma haloperidol levels and plasma reduced haloperidol levels may result from fluoxetine’s inhibitory effect on the liver metabolism of haloperidol.
서 론
연구대상 및 방법
연 구 결 과
고 찰
요 약
참고문헌